Show simple item record

dc.contributor.authorPatel, Ashaben
dc.contributor.authorGupta, Vineet
dc.contributor.authorHickey, John M.
dc.contributor.authorNightlinger, Nancy S.
dc.contributor.authorRogers, Richard S.
dc.contributor.authorSiska, Christine
dc.contributor.authorJoshi, Sangeeta B.
dc.contributor.authorSeaman, Michael S.
dc.contributor.authorVolkin, David B.
dc.contributor.authorKerwin, Bruce A.
dc.date.accessioned2020-11-30T14:58:39Z
dc.date.available2020-11-30T14:58:39Z
dc.date.issued2018-12-01
dc.identifier.citationPatel, A., Gupta, V., Hickey, J., Nightlinger, N. S., Rogers, R. S., Siska, C., Joshi, S. B., Seaman, M. S., Volkin, D. B., & Kerwin, B. A. (2018). Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. Journal of pharmaceutical sciences, 107(12), 3032–3046. https://doi.org/10.1016/j.xphs.2018.08.012en_US
dc.identifier.urihttp://hdl.handle.net/1808/30934
dc.descriptionThis work is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.description.abstractIn this study, we investigated analytical challenges associated with the formulation of 2 anti-HIV broadly neutralizing antibodies (bnAbs), 3BNC117 and PGT121, both separately at 100 mg/mL and together at 50 mg/mL each. The bnAb formulations were characterized for relative solubility and conformational stability followed by accelerated and real-time stability studies. Although the bnAbs were stable during 4°C storage, incubation at 40°C differentiated their stability profiles. Specific concentration-dependent aggregation rates at 30°C and 40°C were measured by size exclusion chromatography for the individual bnAbs with the mixture showing intermediate behavior. Interestingly, although the relative ratio of the 2 bnAbs remained constant at 4°C, the ratio of 3BNC117 to PGT121 increased in the dimer that formed during storage at 40°C. A mass spectrometry-based multiattribute method, identified and quantified differences in modifications of the Fab regions for each bnAb within the mixture including clipping, oxidation, deamidation, and isomerization sites. Each bnAb showed slight differences in the levels and sites of lysine residue glycations. Together, these data demonstrate the ability to differentiate degradation products from individual antibodies within the bnAb mixture, and that degradation rates are influenced not only by the individual bnAb concentrations but also by the mixture concentration.en_US
dc.description.sponsorshipBill and Melinda Gates Foundation, Seattle, WA [grant number OPP1138851 and Investment ID 25617]en_US
dc.publisherWileyen_US
dc.rights© 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectBroadly neutralizing antibodiesen_US
dc.subjectStabilityen_US
dc.subjectCoformulationen_US
dc.subjectMass spectrometryen_US
dc.subjectProtein aggregationen_US
dc.subjectCalorimetry (DSC)en_US
dc.subjectCapillary electrophoresisen_US
dc.subjectDeamidationen_US
dc.subjectOxidationen_US
dc.subjectBiotechnologyen_US
dc.titleCoformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studiesen_US
dc.typeArticleen_US
kusw.kuauthorPatel, Ashaben
kusw.kuauthorGupta, Vineet
kusw.kuauthorHickey, John M.
kusw.kuauthorJoshi, Sangeeta B.
kusw.kuauthorVolkin, David B.
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.1016/j.xphs.2018.08.012en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC6269598en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.
Except where otherwise noted, this item's license is described as: © 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.